Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Description

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Conditions

Renal Cell Carcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Prospective Phase II Study of Stereotactic Body Proton Therapy for Treatment of PrimAry Renal Cell Carcinoma (SPARE)

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Condition
Renal Cell Carcinoma
Intervention / Treatment

-

Contacts and Locations

Washington

Sibley Memorial Hospital, Washington, District of Columbia, United States, 20016

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Age ≥ 18 years
  • 2. Biopsy proven renal cell carcinoma.
  • 3. No clinical or radiographic evidence of metastatic disease.
  • 4. Not a candidate for surgical treatment or local ablative procedures.
  • 5. Subjects are able to undergo either an MRI or administration of contrast agent for CT.
  • 1. Prior history of radiation treatment with overlapping fields.
  • 2. Patients with proven metastatic disease.
  • 3. Female subjects who are pregnant or planning to become pregnant during the treatment.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,

Sherif Shaaban, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2030-08